Ginkgo Results Presentation Deck
Cronos programs contribute both Foundry Revenue and
Equity-Based Commercial Milestones
Foundry Revenue ($M)
$22M total Foundry Revenue
budgeted across 2 major programs
(life of program revenues)
$25
$20
$15
$10
$5
Foundry
$0
$10M
$12M+ (1)
R&D Milestones
Foundry Access Fee
Program
Active Program #1:
CBG(A) At Commercialization
CBC(A)
In Development
CBD(A)
THC(A)
In Development
In Development
Stage
Active Program #2:
CBGV(A)
CBCV(A)
CBDV(A)
THCV(A)
Downstream Value
In Development
In Development
In Development
Development
In
Equity Milestones -
# of Cronos Shares
1,467,490
1,467,490
2,201,236
2,934,981
1,467,490
1,467,490
1,467,490
2,201,236
1)
Foundry Access Fee is a fixed amount paid quarterly; the total amount therefore depends on the length of the program(s).
2) Source: Cronos Q2 2021 earnings call.
3) Value granted upon commercialization and achievement of technical milestones, expected this year; actual value of shares depends on share price. Stock price calculated as of close of market 8/17/2021.
CASE STUDY 1
CRONOS
GROUP
Cronos has reported
they expect to grant
Ginkgo these shares
in 2021 as part of this
program. (2)
Shares are valued at
approximately $9M
at the current share
price.(3)
H1 UPDATE | AUGUST 2021
GINKGO BIOWORKS
18View entire presentation